RaDaR Research

RaDaR Research Papers

1. Distribution of epidemiology and clinical characteristics of RaDaR participants pre-print reporting  (Wong et al MedRxiv, 2023; (https://www.medrxiv.org/content/10.1101/2023.09.24.23296009v1)
2. Long term outcomes in IgA nephropathy Pitcher et al Clinical Journal of the American Society of Nephrology, 2023 https://journals.lww.com/cjasn/fulltext/2023/06000/long_term_outcomes_in_iga_nephropathy.9.aspx

RaDaR Research Posters

1. Barratt et al. Natural History of IgA Nephropathy. Amer Soc Nephrol. 2021
2. Saleem et al. Natural History of FSGS. Amer Soc Nephrol. 2021.
3. Saleem et al. Proteinuria and associated endpoints and association with renal survival in FSGS. Amer Soc Nephrol. 2021.
4. Pitcher et al. Proteinuria and its association with disease progression in IgA nephropathy. Amer Soc Nephrol. Orlando, FL 2022.
5. Wong et al. Genotype and renal outcomes in Alport Syndrome.  Amer Soc Nephrol. Orlando, FL. 2022.
6. Pitcher et al. Proteinuria and its association with disease progression in IgA nephropathy. National Kidney Foundation, Austin TX 2023.
7. Wong et al. The National Registry of Rare Kidney Diseases (RaDaR): cross-sectional analyses of 25,817 adults and children with rare kidney diseases in the UK. UK Kidney Week, Newport, Wales UK 2023
8. Sy et al. Epidemiology of rare kidney diseases in the United Kingdom using a large rare renal registry. ICPE, Halifax Nova Scotia, Canada 2023.
9. Pitcher et al. Proteinuria and Disease Progression in the RaDaR IgA Nephropathy Cohort. International IgA Nephropathy Network, Tokyo, Japan 2023.
10. Downward et al. Development of a De Novo Model To Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin A Nephropathy. ISPOR, Boston, MA 2023
11. Pitcher et al. Rate of Loss of eGFR and Time-Averaged Proteinuria in IgAN Patients Progressing From Early Stage Disease to Kidney Failure. Amer Soc Nephrol. Philadelphia PA 2023.
12. Downward et al. Patient characteristics and renal outcomes of C3G and IC-MPGN in the UK: a retrospective analysis of 287 patients in the UK RaDaR. Amer Soc Nephrol. Philadelphia PA 2023.
13. Gittus et al. Centre-Level Variation in Tolvaptan Prescribing for ADPKD in the UK UKKW 2023
14. Mercer et all. Estimating delay in time to kidney failure or death for treatment effects on proteinuria in IgA nephropathy ERA Congress Milan 2023

Papers using RaDaR data or infrastructure

1. Treatment and long-term outcome in primary distal renal tubular acidosis Nephrology Dialysis Transplantation, Volume 34, Issue 6, June 2019, Pages 981–991.
2. High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults Kidney International, Volume 96, Issue 6, December 2019, Pages 1408-1416.
3. Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol. 2019 Dec;15(12):750-765. doi: 10.1038/s41581-019-0217-5. Epub 2019 Oct 25. PMID: 31654044 
4. Response to First Course of Intensified Immunosuppression in Genetically-Stratified Steroid Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol. 2020 Apr 21:
5. A role for OCRL in glomerular function and disease. Pediatr Nephrol. 2020 Apr;35(4):641-648.
6. TBC1D8B Loss-of-Function Mutations Lead to X-Linked Nephrotic Syndrome via Defective Trafficking Pathways. Am J Hum Genet. 2019 Feb 7;104(2):348-355
7. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy, J Amer Soc Nephrol 2020. Feb;31(2):365-373. doi: 10.1681/ASN.2019040433. Epub 2020 Jan 9. PMID: 31919107
8. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020 Jul;583(7814):96-102. doi: 10.1038/s41586-020-2434-2. Epub 2020 Jun 24. PMID: 32581362